Drugs / anti-rabies mAb
anti-rabies mAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07445815 | Jan → Jul 2026 overdue | — | Lanzhou Institute of Biological Products Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-rabies mAb | “different doses of a recombinant human anti-rabies virus monoclonal antibody injection (referred to as the anti-rabies mAb), administered alone or in combination with a human...” NCT07445815 ↗ |
| Known as | Recombinant Human Rabies Virus Monoclonal Antibody Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07445815 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human Rabies Virus Monoclonal Antibody Injection” NCT07445815 ↗ |
| Route | Intramuscular | “administer via intramuscular injection” NCT07445815 ↗ |